Search Case Studies
UCL research led to the first accepted standard treatment for patients with advanced biliary tract cancer.
The HiLo trial has changed management for patients with well-differentiated thyroid cancer. The new treatment standard is more convenient for patients, with fewer side effects, and reduced costs to the health service.
Research by UCL Virology has defined the natural history and pathogenesis of cytomegalovirus infection and disease. Rapid diagnosis and pre-emptive therapy are now available worldwide for this important infection.
Investigation of the role of CT colonography led to this examination replacing the standard radiological alternative of barium enema in the UK National Bowel Cancer Screening Programme and for symptomatic patients in the NHS.
Research at the UCL Cancer Institute has produced the first promising results using gene therapy to help patients with haemophilia.
Clinicians and scientists at UCL have been central to the design and management of single centre and multi-centre lymphoma trials within the UK and internationally.
CardioQ: Improved surgical outcomes achieved through perioperative circulatory optimisation guided by oesophageal Doppler
A new device – the CardioQ Oesophageal Doppler Monitor – used to monitor critically ill patients and those undergoing high-risk surgery has been used for over half a million patients and is recommended in NICE guidance.
Research on the pathophysiology of transfusion-dependent iron overload in thalassaemia patients has led to a new treatment, deferasirox, and a new method for monitoring patients using MRI.
UCL conducted a series of national lung cancer trials, which led to a switch from chemotherapy with cisplatin to carboplatin-based chemotherapy.
Researchers at the UCL Centre for Rheumatology & Connective Tissue Disease have pioneered translational research in systemic sclerosis, resulting in better stratification, management and treatments for the condition.